Dana Ghiorghiu
- Oncology top 5%
- Colorectal Cancer Treatments and Studies 8
- Pancreatic and Hepatic Oncology Research 4
-
- Lung Cancer Treatments and Mutations 16
- Gastric Cancer Management and Outcomes 4
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism 3
-
- Fibroblast Growth Factor Research 3
-
- Radiomics and Machine Learning in Medical Imaging 3
- Medical Imaging Techniques and Applications 3
- Co-authors
- Myung‐Ju AhnHelen MannJi‐Youn HanNobuyuki KatakamiYi‐Long WuMarina Chiara GarassinoTony MokRachel Hodge
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
Dana Ghiorghiu
35 papers receiving 1.3k citations
Hit Papers
Peers
Comparison fields: 5 of 59
- Oncology 808
- Pulmonary and Respiratory Medicine 929
- Cancer Research 171
- Molecular Biology 497
- Radiology, Nuclear Medicine and Imaging 139
Countries citing papers authored by Dana Ghiorghiu
This map shows the geographic impact of Dana Ghiorghiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dana Ghiorghiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dana Ghiorghiu more than expected).
Fields of papers citing papers by Dana Ghiorghiu
This network shows the impact of papers produced by Dana Ghiorghiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dana Ghiorghiu. The network helps show where Dana Ghiorghiu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Dana Ghiorghiu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 5 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 13 | |
| 6 | 2023 | 0 | |
| 7 | 2023 | 4 | |
| 8 | 2021 | 18 | |
| 9 | TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancerbreakdown → | 2020 | 303 |
| 10 | 2020 | 1 | |
| 11 | 2019 | 7 | |
| 12 | CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)breakdown → | 2018 | 349 |
| 13 | 2017 | 6 | |
| 14 | 2017 | 249 | |
| 15 | 2017 | 22 | |
| 16 | 2016 | 2 | |
| 17 | 2016 | 10 | |
| 18 | 2015 | 25 | |
| 19 | 2013 | 74 | |
| 20 | 2012 | 25 |
About Dana Ghiorghiu
Dana Ghiorghiu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Reproductive Medicine, having authored 36 papers that have together received 1.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (16 papers), Colorectal Cancer Treatments and Studies (8 papers), Pancreatic and Hepatic Oncology Research (4 papers), Gastric Cancer Management and Outcomes (4 papers), Radiomics and Machine Learning in Medical Imaging (3 papers), Medical Imaging Techniques and Applications (3 papers), Fibroblast Growth Factor Research (3 papers) and Cancer, Hypoxia, and Metabolism (3 papers). The work is most often cited by research in Oncology (808 citations), Pulmonary and Respiratory Medicine (929 citations) and Cancer Research (171 citations). Dana Ghiorghiu has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Myung‐Ju Ahn, Helen Mann, Ji‐Youn Han, Nobuyuki Katakami, Yi‐Long Wu, Marina Chiara Garassino, Tony Mok, Rachel Hodge, Vassiliki A. Papadimitrakopoulou and Andy Brown. Their work appears in journals such as JAMA, Journal of Clinical Oncology and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.